We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Editas Medicine (EDIT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Editas Medicine is one of 914 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EDIT's full-year earnings has moved 10.7% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, EDIT has moved about 40.5% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.3% on a year-to-date basis. This means that Editas Medicine is outperforming the sector as a whole this year.
Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 88.9%.
In Amylyx Pharmaceuticals, Inc.'s case, the consensus EPS estimate for the current year increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Editas Medicine belongs to the Medical - Biomedical and Genetics industry, which includes 439 individual stocks and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 5.4% so far this year, so EDIT is performing better this group in terms of year-to-date returns.
On the other hand, Amylyx Pharmaceuticals, Inc. belongs to the Medical - Drugs industry. This 136-stock industry is currently ranked #100. The industry has moved -1.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Editas Medicine and Amylyx Pharmaceuticals, Inc. as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Editas Medicine (EDIT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Editas Medicine is one of 914 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Editas Medicine is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for EDIT's full-year earnings has moved 10.7% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, EDIT has moved about 40.5% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 2.3% on a year-to-date basis. This means that Editas Medicine is outperforming the sector as a whole this year.
Amylyx Pharmaceuticals, Inc. (AMLX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 88.9%.
In Amylyx Pharmaceuticals, Inc.'s case, the consensus EPS estimate for the current year increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Editas Medicine belongs to the Medical - Biomedical and Genetics industry, which includes 439 individual stocks and currently sits at #150 in the Zacks Industry Rank. Stocks in this group have gained about 5.4% so far this year, so EDIT is performing better this group in terms of year-to-date returns.
On the other hand, Amylyx Pharmaceuticals, Inc. belongs to the Medical - Drugs industry. This 136-stock industry is currently ranked #100. The industry has moved -1.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Editas Medicine and Amylyx Pharmaceuticals, Inc. as they could maintain their solid performance.